Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tripterygium glycosides plus dapagliflozin for diabetic nephropathy
ChiCTR2200062581Phase 4Not yet recruiting
- Sponsor
- Yejishan Hospital of Wannan Medical College
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tripterygium wilfordii polyglycosides and dapagliflozin in diabetic glomerulosclerosis (2 arms), sponsored by Yejishan Hospital of Wannan Medical College. Primary endpoints: Urinary albumin-to-creatinine ratio, 24-hour urinary protein and 4 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tripterygium wilfordii polyglycosidesdapagliflozin
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2200062581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062581.